abstract | Microsatellite instability (MSI) is the molecular fingerprint of a deficient mismatch repair system. Approximately 15% of colorectal cancers (CRC) display MSI owing either to epigenetic silencing of MLH1 or a germline mutation in one of the mismatch repair genes MLH1, MSH2, MSH6 or PMS2. Methods to detect MSI are well established and routinely incorporated into clinical practice. A clinical and molecular profile of MSI tumors has been described, leading to the concept of an MSI phenotype in CRC. Studies have confirmed that MSI tumors have a better prognosis than microsatellite stable CRC, but MSI cancers do not necessarily have the same response to the chemotherapeutic strategies used to treat microsatellite stable tumors. Specifically, stage II MSI tumors might not benefit from 5-fluorouracil-based adjuvant chemotherapy regimens. New data suggest possible advantages of irinotecan-based regimens, but these findings require further clarification. Characterization of the molecular basis of MSI in CRC is underway and initial results show that mutations in genes encoding kinases and candidate genes with microsatellite tracts are over-represented in MSI tumors. Transcriptome expression profiles of MSI tumors and systems biology approaches are providing the opportunity to develop targeted therapeutics for MSI CRC.
Introduction
in 1993, seminal articles reported the presence of micro satellite instability (msi) as a frequent molecular pheno menon in colorectal cancers (CrC). [1] [2] [3] since then, a plethora of studies using various approaches have charac terized this molecular subtype. tumors harboring a defi cient mismatch repair (mmr) system owing to germline, somatic or epigenetic inactivation account for approxi mately 15% of CrC diagnosed in the us. 4, 5 although a large population of patients with CrC have a deficient mmr system, msi has only slowly been recognized as a clinically relevant aspect of tumor biology even though it is a well established molecular marker for patients with suspected lynch syndrome. 6 this review provides an introduction to the molecular basis of the mmr system, the detection of msi, and the molecular characteristics of these tumors. in addition, it focuses on the clinical features of msi tumors and the prognostic and predic tive value of msi. Finally, new targeted therapies for the treatment of this tumor subtype are discussed.
Molecular basis of the MMR system
microsatellites are repetitive sequences distributed throughout the human genome that consist of mono nucleotide, dinucleotide or higherorder nucleotide repeats such as (a) n or (Ca) n . these sequence motifs are especially prone to accumulation of mutations, mainly because the Dna polymerases cannot bind Dna effi ciently during Dna synthesis. the most frequent errors associated with microsatellites are base-base mismatches that escape the intrinsic proofreading activity of Dna polymerases, and insertion-deletion loops, which are extrahelical nucleotides that form Dna hairpins. these unpaired nucleotides occur when the first nucleotide and template strand dissociate and incorrectly reanneal in a microsatellite. insertions or deletions in micro satellites located in Dna coding regions generate frameshift mutations, which can lead to protein truncations. 7 the mmr system is responsible for the surveillance and correction of errors introduced in microsatellites ( Figure 1 ), and is highly conserved from bacteria to humans. mlH1, msH2, msH3, msH6 and Pms2 are the main proteins involved in this system, and they interact as heterodimers. when a mismatch is detected, a number of steps take place: msH2 associates with either msH6 or msH3 (forming mutsα and mutsβ complexes, respec tively), and mlH1 couples with Pms2, Pms1 or mlH3 (forming mutlα, mutlβ or mutlγ complexes, respec tively). the recognition of mismatches and insertiondeletion loops is carried out by the complex formed by a muts and a mutl, which interacts with replication factor C. excision of the mismatch is performed by pro teins such as exonuclease 1 and proliferatingcellnuclear antigen. Finally, resynthesis and religation of the Dna strand is carried out by Dna polymerase δ and Dna ligase. 7, 8 mutations in the genes responsible for the recog nition step lead to an accumulation of errors in Dna, which results in msi.
msi has been observed in diverse tumor types, includ ing CrC, gastric, endometrial, ovarian and sebaceous www.nature.com/nrclinonc carcinomas, as well as glioblastoma and lymphomas. 9, 10 First discovered in CrC, the msi phenotype contin ues to serve as the hallmark of defective mmr since it was observed that germline mutations in MLH1, MSH2, MSH6 and PMS2 are responsible for a genetic pre disposition to CrC known as lynch syndrome or hereditary nonpolyposis CrC (HnPCC).
6,11 lynch syn drome is an autosomal dominant disease that accounts for 2-3% of total CrC. 4, 5, 12 a heritable somatic methyla tion of MSH2 has also been reported that is caused by a deletion of the last exon of EPCAM, which is adjacent to MSH2. 13 if germline mutations are harbored in mmr genes, the cumulative risk of developing CrC is 60-70% in men, and 30-40% in women; the cumulative risk of developing endometrial cancer is 40-80%.
5,14,15 most cases of msi CrC are a result of hypermethylation of MLH1. 16 several population based studies have reported that the prevalence of msi in CrC ranges from 8% to 20%, although these values might differ according to tumor stage distribution.
5,13,17,18 msi is more common 
Detection of MSI
msi is detected by PCr amplification of specific micro satellite repeats. the presence of instability is deter mined by comparing the length of nucleotide repeats in tumor cells and normal cells. normal Dna is typically extracted from adjacent normal mucosa. the analysis of amplified Dna was initially performed with denaturing acryla mide gels and radiolabeled primers; however, this process has been made easier with fluorescent primers and capillary electrophoresis ( Figure 2) . 24, 25 in the late 1990s, a consensus conference established a panel of microsatellite markers with appropriate sensitivity and specificity to diagnose msi CrC. this reference panel, known as the Bethesda panel, included five micro satellite loci: two mononucleotides (Bat25 and Bat26) and three dinucleotides (D5s346, D2s123 and D17s250). some clinical and research laboratories have expanded this panel to ten markers, which has made the diagno sis of msi CrC easier.
9,26 three categories of msi have been established based on the following criteria: msi High (msiH), indicating instability at two or more loci (or >30% of loci if a larger panel of markers is used); msilow (msil), indicating instability at one locus (or in 10-30% of loci in larger panels), and microsatellite stable (mss), indicating no loci with instability (or <10% of loci in larger panels). msil cases usually only show instability for dinucleotide markers, so the assessment of dinucleotides alone could lead to the misclassification of mss or msil as msiH. By contrast, mononucleo tides Bat25 and Bat26 are nearly monomorphic, so in the absence of normal control tissue, msi determination could be based on the presence of mononucleotides for most nonafrican populations. 25 the Bethesda panel, therefore, has a sufficient combination of markers for msi. newer commercial kits include a predominance of mononucleotide markers with improved sensitivity.
immunohistochemical analysis of mmr proteins has become a popular alternative to detect msi in the clini cal setting and as a complement to the genetic testing of lynch syndrome. antibodies against mlH1, msH2, msH6 and Pms2 provide insight into the functional ity of the mmr system. lack of expression of one or more of these proteins is diagnostic of deficient mmr, and determines which encoding gene is most likely to harbor a germline mutation or to have been inactivated by another mechanism. interpretation of the immuno histochemical pattern takes advantage of the dependent expression of specific heterodimers in the molecular diagnostic workup of CrC, as illustrated in table 1. 6 as an example, CrC that lack expression of mlH1 and Pms2, but retain expression of msH2 and msH6, rEViEwS represent deficient mlH1 expression (Figure 3 ). in this situation, absent expression of Pms2 is simply a conse quence of the defective mlH1. whether the deficiency of mlH1 is caused by inactivation of the gene by pro moter hypermethylation or a germline mutation that causes lynch syndrome requires further investigation, but immunohistochemistry directs the workup to focus on mlH1 rather than the other mmr proteins.
Molecular features of MSI tumors
the msi phenotype is strongly associated with muta tions in specific oncogenes and tumor suppressor genes, especially BRAF and MRE11A, and also in others, such as KRAS. the majority of CrC is characterized by genetic instability that arises through loss or gain of chromosome arms, chromosomal translocations or gene amplifica tions ( Figure 4 )-these tumors are termed chromo somal in stable (Cin) tumors. 27 the multistep model of adenoma progression to carcinoma proposed by Fearon and vogelstein nearly two decades ago, outlines the contribution of somatic mutation events to the patho genesis of CrC and continues to serve as a meaningful, although incomplete model of the develop ment of Cin tumors ( Figure 4a ). 28 By contrast, msi CrC tend to show a stable karyotype (Cin negative), and genetic instabi lity in this subtype of CrC primarily reflects variation in microsatellite tracts owing to a defective mmr system ( Figure 4b ). more than 30 genes have mutations arising in microsatellite repeats in mmr deficient tumors, and these genes are implicated in diverse cellular functions and pathways. some examples are the Dna repair pro teins mre11a and hraD50, the growth factors tGFβ receptor ii and iGF receptor ii, the proapoptotic factor BaX, the mismatch repair proteins msH3 and msH6 and the histone modifier HDaC2. 29 although muta tions in these pathways are not unique to msi CrC, the importance of the resultant events could lead to ways of exploiting these specific genes and pathways as potential drug targets and markers of sensitivity to therapies. mutations in genes encoding kinases are attractive for clinical researchers because of their notable contribution to tumorigenesis and potential therapeutic value. For example, BRAF encodes a serine/threonine kinase that acts upstream of maPKK1 and maPKK2 in response to ras signals, and is an essential component of the raF/meK/erK/maPK kinase signaling cascade. BRAF mutations are present in 10% of CrC and are mutually exclusive with KRAS mutations. 30, 31 most of the muta tions in BRAF are located in a hotspot located in exon 15, which leads to a v600e singleaminoacid substitution. strikingly, BRAF mutations in colorectal tumors are more frequent in sporadic msi tumors than in hereditary cases, and are caused by hypermethylation of MLH1. 31, 32 moreover, clinicians have taken advantage of the absence of BRAF mutations in lynch syndrome cases to rule out the sporadic origin of msi tumors displaying a genetic background. 33, 34 overall, this fact highlights the strong association that exists between sporadic msi and the presence of the v600e BRAF mutation. although a BRAF mutation profoundly reduces the probability of a diagnosis of lynch syndrome, it does not entirely exclude the possibility. [35] [36] [37] KRAS mutations, however, are more likely to be observed in mss (Cin) cancers than msi tumors, which is consistent with the original description of these mutations as early key events that lead to intermediate adenomas within the pathogenesis of sporadic CrC. 28 indeed, KRAS mutations are present in approximately 40% of colorectal primary tumors. 38 thus, msi tumors generally have fewer KRAS mutations than mss tumors, and the mutational pattern differs in Cin versus msi cancers.
in addition to these specific mutational profiles, a description of the genomic landscape of CrC points to the phosphatidylinositol 3kinase (Pi3K) pathway as a driver of tumorigenesis. 39 initially, PIK3CA was a focus of attention because it has a key regulatory role in this pathway and was reported to be mutated in 30% of colo rectal tumors. 40 subsequent studies found lower mutation 48 msi tumors were initially thought to have more mutations in PIK3CA than in mss CrC, 40, 47 but these results have not been confirmed. Discrepancies could be related to differences in tumor stage, patient ethnicity and numbers of exons screened. PTEN, which is the only tumor suppressor in this pathway, is not only mutated but also epigenetically silenced with higher frequency in msiH tumors than msil or mss tumors (19.1% versus 2.2%). 48, 49 Gene-expression profiling of MSI several groups have studied the differences in gene expression between msi and mss in tumors [50] [51] [52] [53] [54] and cell lines 55 by use of highthroughput technologies. most of these studies excluded tumors displaying msil or grouped them with mss cases. 50, 51, 53 in addition, only one of these studies included sufficient lynch syndrome cases to enable assessment of the differences in gene expression between familial and sporadic msi cases. 54 the diver sity of the genetic profiles generated from these studies could be related to technical differences in experi mental approaches, selective reporting of fractions of differen tially expressed transcripts, or true differences in the expression profiles of the tumors represented in these studies. 56 studies evaluating the prognostic performance of gene signatures in breast cancer have driven important clinical trials, such as minDaCt (nCt00433589) 57 and the tailorx trial (nCt00310180). 58 table 2 summa rizes the data generated from six groups describing gene expression profiles for msi tumors. the partial overlap of the gene list is notable, especially since many were gener ated using the same gene platform approach. moreover, enrichment analyses derived from these profiles have shown that the overlapping features of the expression patterns are linked to immune responses and inter leukin pathways. these pathways are related to the high numbers of tumorinfiltrating lymphocytes observed in msi tumors. 59 this observation is consistent with the strong immune response that msi tumors elicit in the host, which can be observed histologically.
in contrast to the small overlap of gene lists assessed in some studies, high levels of reproducibility and con cordance between several msi data sets have also been reported. 60 reanalysis of published data sets with new parameters has yielded a common level of significance for all of the data sets (P <0.05). moreover, this high level of concordance between different msi data sets was extended to the comparison of tumor samples and established cell line counterparts. these results highlight rEViEwS three principles of geneexpressionprofiling studies: direct comparison of expression profiles generated from different sample sets, laboratories and platforms could give a false sense of inconsistency; the limited number of samples of any individual expression profiling study emphasizes the importance of public access to the original expression data; and further statistical method develop ment is warranted to improve metaanalytical approaches for large expression data sets and find the optimal way to combine the analytical results from these different data sets. this last point is especially critical, not only for expression analysis in msi CrC, but also for other relatively small subtypes, such as lynch syndrome cases as well as sporadic msi cancers with or without BRAF mutations. Power calculations show that a minimum of 56 tumors per group is needed to achieve a false discov ery rate of <5% for a signature of 200 genes with a twofold difference between two groups. 56 this sample size is large for these subtypes as the incidence is <15% of all CrC. therefore, metaanalyses combining geneexpression data of samples from different sources and studies would make these comparisons more feasible.
Finally, highthroughput technologies could help to provide more information on two important issues: what forms of gene expression are different between fami lial and sporadic msi tumors, and whether msil is a sepa rate subtype to mss to define whether msi follows a tri modal distribution (msiH versus msil versus mss) or a bimodal distribution (msi versus mss). 25 until this issue is clarified, combining msil with mss for outcome studies remains reasonable given that msil cases resemble mss tumors rather than msi tumors.
Features and applications of MSI
a recognizable clinicopathological profile of msi tumors has been established from clinical studies. CrC display ing msi tend to be rightsided and diagnosed at lower pathological stages compared with mss cancers. the age distribution of msi cancers follows a ushaped distribu tion, and sporadic msi cases are generally diagnosed in older patients (>70 years of age) whereas familial cases are younger (<50 years of age). 61 CrC generally have high histological grades, mucinous phenotypes with promi nent numbers of tumorinfiltrating lymphocytes, a lack of necrotic cellular debris within the lumen of the neo plastic glands in the colorectal mucosa (dirty necrosis) and a Crohnlike host response. these features can be successfully combined to predict the likelihood of the presence of msi in tumor samples. 17 Figure 4 | CRC progression models and therapeutic targets in MSI and MSS CRC. Molecular CRC groups based on a | chromosomal instability and b | the mutator phenotype. The genetic models for CRC tumorigenesis are presented in parallel for each pathway of tumor development. Targeted therapies based on molecular events are also presented for MSI tumors. Abbreviations: CRC, colorectal cancer; MSI, microsatellite instability; MSS, microsatellite stable.
rEViEwS CrC, prediction of response to chemotherapeutic agents, such as 5fluorouracil (5Fu) and irinotecan, and genetic assessment of lynch syndrome.
Prognostic value of MSi in crc
Gryfe et al. 17 reported the first cohort of patients in whom the prognostic importance of defective mmr was demon strated. msi tumors had a more favorable prognosis and were less prone to lymphnode spread and metastasis than mss tumors. these results have been corroborated by many subsequent studies, includ ing the large series reported by watanabe et al. 63 a meta analysis assessed individual clinical data from 32 studies that included 7,642 CrC cases, where 1,277 of these cases displayed msi. 64 this metaanalysis confirmed the prog nostic advantage of msi. moreover, a presentation at the asCo 2009 annual meeting reported that the prog nostic value of msi is more prominent in stage ii than stage iii CrC cases. 19 Despite the repro ducibility of these data, msi testing has not been routinely incorporated into practice to inform patients about their prognosis or to guide therapeutic decisionmaking.
MSi as a predictor of 5-FU efficacy the value of msi as a predictive marker of response to 5Fu, irinotecan and other chemotherapeutic agents remains controversial. Conflicting results have been published during the past decade and are summarized in table 3. 62,65-74 the value of msi as a marker of response to 5Fu was described in a study where msi cancers were associated with better response to a 5Fubased regimen than mss cancers. 66 this observation is not supported by subsequent studies. several factors could explain the dif ferences in these results. First, sample sizes are generally too small to show an effect of chemo therapy treatments in patient subgroups stratified by mmr status. 66 this point has been addressed in a metaanalysis that confirmed the lack of predictive value of msi for outcomes with 5Fu regimens. 74 second, the results may have been affected by the retrospective and single institutional nature of most of the studies, which used different methods and criteria to evaluate the presence of msi. Finally, the inadequate interpretation of the data might have been a contributing factor to these results. interpretation of data is particu larly relevant as these studies analyzed the effects of 5Fu in patients with msiH CrC. ideally, predictive data analysis should be performed for every tumor subtype. this method would approximate a clinical trial, where the intervention group is compared with the control group and stratified by mmr status. this approach has been effectively utilized in several, but not all studies of msi. 65, 69, 70, 73 the data presented by sargent et al. 73 at the 2008 asCo annual meeting are particularly noteworthy. this large retrospective study included samples obtained from six randomized, controlled trials analyzing the benefit of 5Fubased adjuvant chemotherapy in patients with stage ii and iii CrC. regimens combining oxaliplatin, irinotecan and oral fluoropyrimidines were excluded. in addition, analysis of the efficacy of 5Fu in msi cases was restricted to stage ii patients because adminis tration of adjuvant chemotherapy to stage iii patients is cur rently the standard of care. sargent et al. 73 concluded that patients receiving 5Fu had no advantage over those who did not receive 5Fu and this treatment might even be harmful for stage ii cases displaying msi. these findings were, however, interpreted specifically for stage ii cancers and generalization to other stages might not be possible. adjuvant combined chemotherapy with a 5Fubased regimen remains the standard of care in patients diag nosed with stage iii disease, regardless of msi status. an ongoing clinical trial is exploring the role of msi and loss of 18q as predictive factors to guide therapeutic deci sions on the use of adjuvant therapy for stage ii cases (eCoGe5202). 75 the study design has been criticized, however, because the results from the PetaCC3 study showed that loss of 18q has no prognostic value for stage ii CrC. 19 Definitive interpretation of the value of msi as a predictive factor for 5Fubased chemotherapy based on this trial will, therefore, be difficult.
Finally, the predictive value of msi for 5Fubased therapies has been debated as there are reports of increased sensitivity to this drug in tumors displaying CpG island methylator phenotype (known as CimP High). 76 such divergence could be related to the fact that the CimPHigh subtype includes other tumors with molecular features that are different to msi, such as hyper methylation of MGMT. 77 MSi as a predictor of irinotecan efficacy evidence supporting the preferential efficacy of irino tecan in msi tumors is continuing to emerge, but is still considered preliminary. [78] [79] [80] [81] this chemotherapy agent is a semisynthetic, water soluble camptothecin analog and a potent inhibitor of the topoisomerase i enzyme. topoisomerase i generates a transient nick in one of the rEViEwS Dna strands during replication and transcription, which allows the Dna to relax. irinotecan binds to the Dnatopoisomerase i complex and traps it, thus preventing religation of the Dna. the replication and transcrip tion machinery collides with the Dna-topoisomerase i complex, generating a double strand break. if this dys function is unresolved by the Dna repair system, it even tually leads to apoptosis and cell death. 82 Doublestrand breaks can be repaired by two different mechanisms: homologous recombination and nonhomologous end joining. Homologous recombi nation is activated after replication when a second identical Dna copy is avail able, making this pathway errorfree. nonhomologous end joining occurs when no Dna template is available and this system is prone to errors. mechanisms involved in homologous recombination are complex and beyond the scope of this article, but the function of the mre11a/ hraD50/nBs1 (mrn) complex in this pathway should be highlighted based on its potential role in the response to irinotecan.
Four preclinical studies have suggested that msi cell models are especially sensitive to irinotecan com pared with their proficient counterparts. [78] [79] [80] [81] although the molecular basis of this increased sensitivity is not fully defined, msi CrC cell lines tend to accumulate mutations in microsatellites located in an intron-exon boundary polyt(11) repeat in MRE11A and in a coding polya(9) tract in hRAD50. Cell lines harboring these mutations also show a particularly high sensitivity to irinotecan. 78 moreover, functional work by rodriguez et al. 81 shows that MRE11A deficiency or mutations promote sensiti vity to camptothecins. the mss CrC cell line sw480 was treated with small interfering rna directed to MRE11A or was stably transfected, and these manipulations led to a frameshift mutation in the MRE11A gene. transfected cells were more sensitive to camptothecins than their wildtype counterparts. 81 these experiments provide evidence that secondary mutations in genes that control repair of doublestrand breaks are the cause of the increased sensitivity rather than the abnormal mmr itself. an abnormal mmr system does not, however, always result in MRE11A deficiency. mutations in this gene are detected in 70-85% of msi tumors, 83, 84 making msi an imperfect surrogate marker for increased sensiti vity to irinotecan.
Four clinical studies have analyzed the activity of irino tecan in msi CrC. the first is a retrospective study analy zing a cohort of 72 patients with metastatic CrC treated with irinotecan in a single institution and stratified by microsatellite status. 85 the second study is a prospective analysis of a cohort of 702 stage iii CrC patients included in the CalGB protocol 89803 study that evaluated the efficacy of a combination of agents (irinotecan, 5Fu and folinic acid) compared with a weekly bolus of 5Fu as adjuvant therapy. 86 Predictive analysis showed a trend towards a higher benefit of msiH tumors treated with Note that the majority of these trials are observational studies and some of them have retrospectively reviewed tumors collected in the context of randomized, controlled trials. Abbreviations: CT, chemotherapy; DFS, disease-free survival; FO, folinic acid; 5-FU, 5-fluorouracil; LEV, levamisol; MA, meta-analysis; mDFS, median disease-free survival; mOS, median overall survival; MSI-H, microsatellite instability-high; MTX, methotrexate; NR, non-randomized; OS, overall survival; P, prospective; R, retrospective; RCT, randomized controlled trial.
rEViEwS the combined regimen in terms of 5year diseasefree survival, although it did not reach significance. Patients with mss tumors were not likely to obtain any benefit with the addition of irinotecan to 5Fu. 86 Data presented by tejpar et al. 87 at the 2009 asCo annual meeting, however, did not confirm this observation. in this study, a retrospective analysis of 1,254 patients included in the PetaCC3 trial was performed to assess the effect of the folinic acid, 5Fu and irino tecan regimen as adjuvant therapy compared with the de Gramont infusional 5Fu and folinic acid regimen in stage ii and iii CrC patients. among 188 msiH cases, those treated with irinotecan did not demonstrate improved survival. 87 the third study is a retrospective review of data from the Cairo trial, which included sequential irinotecancontaining treat ments for stage iv CrC. 20 unfortunately, because only a limited number of the CrC cases were msi tumors (14 of 515) and both treatment arms included irino tecan at some point, clear interpretation of the msi data was not possible. Finally, a metaanalysis on the effect of chemo therapy in stage iv patients displaying msi, including the studies by Fallik et al. 85 and the Cairo trial, 88 did not achieve enough power to draw any conclusions about the effect of irinotecanbased regimens. 89 more studies need to be carried out to clarify the role of chemotherapy regimens containing irinotecan in msi tumors.
genetic assessment of lynch syndrome the role of msi as a genetic marker of lynch syndrome is well established in the clinic. Both msi detection and immunohistochemistry are highly sensitive methods for the identification of individuals with defective mmr, and guide clinicians towards informative, costeffective genetic testing. Data are, however, currently insufficient to enable recommendation of a strategy based on one tech nique or a preferred sequence of both for the detection of msi tumors in a population. 90 Tailored therapies for MSI tumors the development of therapeutic strategies for msi tumors has traditionally followed a process centered on signaling pathways. the identification of a molecular event could lead to the development of an agent that exploits the deficiency or the hyperactivation of pathways that are caused by specific molecular events; for example, ParP1 inhibition in BRCA1 and BRCA2 mutant breast and ovarian cancers, or KIT mutations in gastrointestinal stromal tumors. Gene expression data have been imple mented as a way to improve and refine the drug discovery process. the identification of deregulated pathways or geneexpression profiles defining subtypes of tumors has led to the possibility of developing compounds according to the concept of genomiccentered therapeutics. 91 as an example, we have found evidence of pathway centered signaling in msi CrC. 92 ParP1 inhibitors represent an attractive target in msi tumors since there seems to be a deficient doublestrandbreak repair system related to mutations in the coding micro satellites of hRAD50 and MRE11A. the effect of ParP1 inhibi tors in msi cell lines were tested, therefore, and the expression level of mre11a was correlated with drug response. 92 although these data need to be confirmed in other settings, they suggest that specific mutations can be used to exploit the concept of synthetic lethality in msi tumors, which has been successful in BRCA1 mutant breast cancers. 93 another example explores the activity of demethylating agents in msi cell line models. a particular frameshift mutation of HDAC2 located in a coding polya9 repeat of exon 1 determined the lack of response in msi cells to certain histone deacetylase inhibitors, such as trichostatin a, but not to others, such as butyric acid and valproic acid. 94 this result is due to biochemical differences that limit the access of these drugs to catalytic sites. these two examples demonstrate that genetic instability owing to msi could represent an achilles' heel of specific subtypes of cancer that can be therapeutically targeted.
Despite incomplete overlap, geneexpression data might have the potential to identify new therapies for msi tumors. 52 with the use of a systems biology tool called Connectivity map, it was shown that both siro limus and lY294002 (compounds that target the Pi3K/ aKt/mtor pathway) induce gene expression changes with negative correlation to expression patterns in msi tumors. sirolimus and lY294002 were then confirmed in vitro to be selective inhibitors for msi cell lines. these results highlight the relevance of the Pi3K/aKt/mtor pathway in this tumor subtype and have uncovered new potential targets for drug discovery. 52 although CrC comprise a heterogenous group of cancers, recognition of the msi phenotypes draws atten tion to the value of understanding specific subtypes of cancer. the data suggest it is worthwhile devoting sub stantial efforts towards designing clinical trials for CrC subtypes and assessing the efficacy of compounds that have mechanisms of action linked to specific molecular characteristics based on data generated not only from singlegene, but also pathway and genomecentered dis coveries. an ongoing phase ii clinical trial (Cinatra) is exploring the effect of a new microtubule inhibitor patu pilone (eP0906) in a cohort of patients displaying msi. 90 this trial is based on the hypothesis that karyotypically stable colorectal tumors (Cin positive) will be more sensitive to antimicrotubule agents than karyotypically instable tumors (Cin negative). this study and others like it represent an important paradigm for advancing treatment options for patients with CrC.
Conclusions
msi is a molecular subtype of CrC that displays a well defined histopathological and therapeutic profile distinct from other molecular subtypes. molecular techniques developed during the past two decades allow reliable detection of msi. although these techniques are acces sible to molecular pathology laboratories, the oncology community has yet to fully embrace msi detection in routine clinical practice with respect to its prognostic and predictive role. emerging data from welldesigned clinical trials should provide further support for clinical utility and implementation.
rEViEwS Drug development strategies focused on specific molec ular subtypes clearly represent the future of cancer thera peutics. Clinical trials based on molecular classifications are likely to have stronger rationales than prior studies, and will increase the likelihood of obtaining a relevant therapeutic response, thus improving the health and well being of patients. msi CrC are ideal for the implemen tation of this strategy based on a compelling rationale motivated by molecular, clinical, pathological, prognos tic and predictive studies that are already changing the practice of oncology.
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